(Q29620676)

9 January 2018

title

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer (English)

1 reference

9 January 2018

1 reference

8

1 reference

9 January 2018

Gabriel N Hortobagyi

21

Gabriel N Hortobagyi

1 reference

9 January 2018

Hope Rugo

5

Hope S Rugo

1 reference

9 January 2018

Denise A Yardley

13

Denise Yardley

1 reference

9 January 2018

Thomas Bachelot

16

Thomas Bachelot

1 reference

9 January 2018

author name string

José Baselga

1

1 reference

9 January 2018

Mario Campone

2

1 reference

9 January 2018

Martine Piccart

3

1 reference

9 January 2018

Howard A Burris

4

1 reference

9 January 2018

Tarek Sahmoud

6

1 reference

9 January 2018

Shinzaburo Noguchi

7

1 reference

9 January 2018

Kathleen I Pritchard

9

1 reference

9 January 2018

Fabienne Lebrun

10

1 reference

9 January 2018

J Thaddeus Beck

11

1 reference

9 January 2018

Yoshinori Ito

12

1 reference

9 January 2018

Ines Deleu

14

1 reference

9 January 2018

Alejandra Perez

15

1 reference

9 January 2018

Luc Vittori

17

1 reference

9 January 2018

Zhiying Xu

18

1 reference

9 January 2018

Pabak Mukhopadhyay

19

1 reference

9 January 2018

David Lebwohl

20

1 reference

9 January 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22149876

language of work or name

1 reference

30 April 2017

publication date

7 December 2011

1 reference

9 January 2018

The New England Journal of Medicine

published in

1 reference

9 January 2018

volume

366

1 reference

9 January 2018

page(s)

520-529

1 reference

9 January 2018

issue

6

1 reference

9 January 2018

Novel agents and future directions for refractory breast cancer

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

New strategies in estrogen receptor-positive breast cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

mTOR and cancer: many loops in one pathway.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Aromatase inhibitors in breast cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Toxicity and response criteria of the Eastern Cooperative Oncology Group

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705195

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22149876

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22149876

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1109653

1 reference

9 January 2018

OpenCitations bibliographic resource ID

332069

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

9 January 2018

PubMed ID

22149876

1 reference

9 January 2018